Modella AI announced that it has been acquired by AstraZeneca (AZN), expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio. The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI’s generative and agentic AI platform into AstraZeneca’s oncology research and development organization. The financial details of the transaction were not disclosed.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Deepens Its Rare Disease Footprint With New Real‑World NMOSD Study in Russia
- AstraZeneca Advances Prostate Cancer Pipeline With New ANDROMEDA Trial on AZD9750
- AstraZeneca Builds Real-World Edge in Rare Neuromuscular Disease With New Russian gMG Study
- AstraZeneca’s AZD5004 Diabetes Trial Reaches Key Phase IIb Milestone
- Illumina introduces Billion Cell Atlas